Ekaterina Dadachova, Ph.D., is a nuclear medicine expert who has done pioneering work using radioimmunotherapy, a technology in which radioisotopes are piggybacked onto antibodies. After the antibodies deliver the radioisotope to a speciﬁc target such as a cancer cell or disease-causing microbe, the radioisotope delivers a lethal dose of radiation. In partnership with Einstein colleague Arturo Casadevall, M.D., Ph.D., Dr. Dadachova developed radioimmunotherapy for metastatic melanoma—a treatment strategy that has shown promise in human clinical trials. In a project supported by the Bill and Melinda Gates Foundation, Drs. Dadachova and Casadevall are also developing a radioimmunotherapy strategy with the potential for treating or perhaps even curing HIV/AIDS by targeting HIV-infected cells. In other novel applications of targeted therapy, Dr. Dadachova is testing radioimmunotherapy against antibiotic-resistant microbes and as a treatment for virus-caused cancers such as cervical cancer and hepatitis B–related liver cancer. Dr. Dadachova is professor of radiology (nuclear medicine) and of microbiology & immunology and is the Sylvia and Robert S. Olnick Faculty Scholar in Cancer Research.